Literature DB >> 18806337

Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004.

Satoru Arai1, Yasuko Matsunaga, Tomohiko Takasaki, Keiko Tanaka-Taya, Kiyosu Taniguchi, Nobuhiko Okabe, Ichiro Kurane.   

Abstract

Japanese encephalitis (JE) surveillance has been conducted since 1965 as a part of the National Epidemiological Surveillance of Vaccine Preventable Diseases in Japan. Over 1,000 JE cases were reported annually in the late 1960s. The number of JE cases has since markedly decreased, with less than 10 cases reported annually from 1992 to 2004. A total of 361 JE cases were reported between 1982 and 2004. Prognosis was available for 320 cases; 58 (18%) died, 160 (50%) recovered with neuropsychiatric sequelae, and 102 (32%) completely recovered. Seventy-eight percent of these cases were 40 years old or over with a peak age group of 60-69 years old. JE predominantly occurred in unvaccinated populations. A high seroconversion rate among sentinel pigs was recorded every year. This suggests the presence of JE virus-infected mosquitoes during the summer in most areas of Japan, including the northern districts where no JE cases were reported from 1982 to 2004. Although JE cases have been reported in single figures since 1992, the risk of JE virus infection is still present. Thus, high immunization rates of JE vaccine should be maintained in Japan.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806337

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  32 in total

1.  Investigation of the genotype III to genotype I shift in Japanese encephalitis virus and the impact on human cases.

Authors:  Na Han; James Adams; Wei Fang; Si-Qing Liu; Simon Rayner
Journal:  Virol Sin       Date:  2015-08-18       Impact factor: 4.327

2.  Epidemiological Features of Japanese Encephalitis in Taiwan from 2000 to 2014.

Authors:  Yu-Kang Chang; Hsiao-Ling Chang; Ho-Sheng Wu; Kow-Tong Chen
Journal:  Am J Trop Med Hyg       Date:  2016-11-07       Impact factor: 2.345

3.  Clinical Characteristics of Severe Japanese Encephalitis: A Case Series from South Korea.

Authors:  Jun-Sang Sunwoo; Soon-Tae Lee; Keun-Hwa Jung; Kyung-Il Park; Jangsup Moon; Ki-Young Jung; Manho Kim; Sang Kun Lee; Kon Chu
Journal:  Am J Trop Med Hyg       Date:  2017-08       Impact factor: 2.345

Review 4.  Estimated global incidence of Japanese encephalitis: a systematic review.

Authors:  Grant L Campbell; Susan L Hills; Marc Fischer; Julie A Jacobson; Charles H Hoke; Joachim M Hombach; Anthony A Marfin; Tom Solomon; Theodore F Tsai; Vivien D Tsu; Amy S Ginsburg
Journal:  Bull World Health Organ       Date:  2011-08-03       Impact factor: 9.408

Review 5.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

6.  Development of a vaccine to prevent Japanese encephalitis: a brief review.

Authors:  Viroj Wiwanitkit
Journal:  Int J Gen Med       Date:  2009-12-29

7.  Seroprevalence of Japanese encephalitis virus infection in captive Japanese macaques (Macaca fuscata).

Authors:  Hiroshi Shimoda; Akatsuki Saito; Keita Noguchi; Yutaka Terada; Ryusei Kuwata; Hirofumi Akari; Tomohiko Takasaki; Ken Maeda
Journal:  Primates       Date:  2014-04-19       Impact factor: 2.163

8.  Evidence and rationale for the World Health Organization recommended standards for Japanese encephalitis surveillance.

Authors:  Susan Hills; Alya Dabbagh; Julie Jacobson; Anthony Marfin; David Featherstone; Joachim Hombach; Pem Namgyal; Manju Rani; Tom Solomon
Journal:  BMC Infect Dis       Date:  2009-12-29       Impact factor: 3.090

Review 9.  Japanese encephalitis - the prospects for new treatments.

Authors:  Lance Turtle; Tom Solomon
Journal:  Nat Rev Neurol       Date:  2018-04-26       Impact factor: 42.937

10.  The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control.

Authors:  Kirsten S Vannice; Susan L Hills; Lauren M Schwartz; Alan D Barrett; James Heffelfinger; Joachim Hombach; G William Letson; Tom Solomon; Anthony A Marfin
Journal:  NPJ Vaccines       Date:  2021-06-15       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.